← Back to Clinical Trials
Recruiting NCT07596966

NCT07596966 EFFECTS OF PROPOLIS AND ROYAL JELLY SUPPLEMENTATION ON INFLAMMATORY AND OXIDATIVE STRESS MARKERS IN PATIENTS WITH SYSTEMIC ARTERIAL HYPERTENSION

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07596966
Status Recruiting
Phase
Sponsor Universidade Federal Fluminense
Condition Systemic Arterial Hypertension
Study Type INTERVENTIONAL
Enrollment 48 participants
Start Date 2025-10-15
Primary Completion 2026-12-10

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
PlaceboRoyal Jelly + Propolis Group

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 48 participants in total. It began in 2025-10-15 with a primary completion date of 2026-12-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The study aims to evaluate the effect of the royal jelly and propolis on inflammation and oxidative stress in participants with systemic arterial hypertension. A longitudinal double-blind randomized clinical trial will be carried out, involving hypertensive participants for two months.

Eligibility Criteria

Inclusion Criteria: * Diagnosis of stage 1 and 2 hypertension * Regular treatment for more than 6 months * There have been no changes in medication doses over the last three months. Exclusion Criteria: * Autoimmune and infectious diseases, diabetes * Chronic kidney disease, liver disease, cancer and AIDS * Pregnant women * Use of catabolic drugs or antibiotics * Use of antioxidant vitamin supplements, prebiotics, probiotics, symbiotic * Habitual intake of royal jelly and propolis

Contact & Investigator

Central Contact

Denise Mafra, PhD

✉ dmafra30@gmail.com

📞 +5521985683003

Principal Investigator

Ludmila Cardozo, PhD

STUDY DIRECTOR

Universidade Federal Fluminense

Frequently Asked Questions

Who can join the NCT07596966 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Systemic Arterial Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07596966 currently recruiting?

Yes, NCT07596966 is actively recruiting participants. Contact the research team at dmafra30@gmail.com for enrollment information.

Where is the NCT07596966 trial being conducted?

This trial is being conducted at Niterói, Brazil.

Who is sponsoring the NCT07596966 clinical trial?

NCT07596966 is sponsored by Universidade Federal Fluminense. The principal investigator is Ludmila Cardozo, PhD at Universidade Federal Fluminense. The trial plans to enroll 48 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology